Orion Oyj (ORINF) Stock Price, News & Analysis

Company Overview

Orion Oyj is a Finland-based pharmaceutical and diagnostic products company that develops, manufactures and markets both human and veterinary medicines, diagnostic tests and active pharmaceutical ingredients. With a history dating back to its founding in 1917, the company has evolved into a diversified life science group, offering prescription and over-the-counter products for neurological, respiratory, cardiovascular and urological conditions, among others. Orion’s human pharmaceuticals portfolio includes well-known treatments for Parkinson’s disease, hormone therapy and erectile dysfunction, while its veterinary range addresses animal health needs such as pain management and dermatology.

In its Diagnostics segment, Orion produces laboratory tests and instruments for clinical chemistry and immunoassay applications, focusing on hormone and drug monitoring. These diagnostic products support healthcare providers and research institutions in more than 90 countries, facilitating patient care and scientific study. The company’s Active Pharmaceutical Ingredients (API) unit supplies customized chemical compounds and intermediates to third-party drug manufacturers, leveraging advanced chemistry capabilities built over decades of pharmaceutical expertise.

Headquartered in Espoo, Finland, Orion combines research and development activities with manufacturing operations in Europe and Asia. The company invests significantly in its R&D centers to discover and advance new molecular entities and formulations, partnering with academic institutions and biotech firms to expand its drug pipeline. Orion also maintains quality-focused production sites, ensuring compliance with international regulatory standards and supporting global distribution networks.

Orion’s governance structure features an executive leadership team headed by a President and CEO and overseen by a Board of Directors. The company’s long-term strategy emphasizes innovative drug discovery, expansion of specialty pharmaceuticals and growth in diagnostics markets. Through sustainable practices and stakeholder engagement, Orion strives to address unmet medical needs, enhance patient outcomes and deliver value to healthcare systems worldwide.

Key Stats

• Today's Range: $82.75 to $82.75
• 50-Day Range: $82.75 to $82.75
• 52-Week Range: $78.95 to $82.75
• Volume: N/A
• Average Volume: 1,080 shs
• Market Capitalization: N/A
• P/E Ratio: 51.50
• Dividend Yield: 1.51%
• Price Target: N/A
• Consensus Rating: N/A

Orion Oyj Stock Analysis - MarketRank™

Orion Oyj scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Orion Oyj.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Orion Oyj is 51.50, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 45.58.

Price to Earnings Ratio vs. Sector

The P/E ratio of Orion Oyj is 51.50, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 270.85.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Orion Oyj has a short interest ratio ("days to cover") of 141.77, which indicates bearish sentiment.

Change versus previous month

Short interest in Orion Oyj has recently decreased by 10.00%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Orion Oyj is a leading dividend payer. It pays a dividend yield of 5.22%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Orion Oyj does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Orion Oyj is 77.80%. Payout ratios above 75% are not desirable because they may not be sustainable.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Orion Oyj this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Orion Oyj insiders have not sold or bought any company stock.

Percentage Held by Institutions

18.76% of the stock of Orion Oyj is held by institutions.

Company Calendar

• Today: 8/17/2026
• Next Earnings (Estimated): 10/28/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ORINF
• CIK: N/A
• Web: www.orion.fi
• Phone: 358104261
• Fax: N/A
• Employees: 3,819
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 51.50
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A